The Gym of the Future Is Here.
See what’s changing and where operators are investing.
Early clinical trial results show that apitegromab dramatically reduced lean mass loss in people taking tirzepatide, the main ingredient in Mounjaro.
Zepbound helped patients lose more weight than Wegovy in a 72-week trial, with greater reductions in both body weight and waist size.
According to Barclays, the weight-loss drug industry could even climb as high as $200 billion within the next decade.
Sign Up to Our Newsletter